H e m a t o lo g y E d u c a t io n - European Hematology Association
H e m a t o lo g y E d u c a t io n - European Hematology Association
H e m a t o lo g y E d u c a t io n - European Hematology Association
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
ern era of BCR-ABL1 tyrosine kinase inhibitors: practical<br />
advice on the use and interpretat<strong>io</strong>n of monitoring methods.<br />
B<strong>lo</strong>od. 2008; 11:1774-80.<br />
20. Quintas-Cardama A, Cortes J, O’Brien S, et al. Dasatinib early<br />
intervent<strong>io</strong>n after cytogenetic or hemato<strong>lo</strong>gic resistance to<br />
imatinib in patients with chronic mye<strong>lo</strong>id leukemia. Cancer.<br />
2009;115:2912-21.<br />
21. Kantarjian H, Giles F, Bhalia K et al. Ni<strong>lo</strong>tinib is effective in<br />
patients with chronic mye<strong>lo</strong>id leukemia in chronic phase after<br />
imatinib resistance or intolerance: 24-month fol<strong>lo</strong>w-up results.<br />
B<strong>lo</strong>od. 2010 November 22. [Epub ahead of print as doi:<br />
10.1182/b<strong>lo</strong>od-2010-03-277152]<br />
22. Hochhaus A, Kantarjian H, Baccarani M, et al. Dasatinib<br />
induces notable hemato<strong>lo</strong>gic and cytogenetic responses in<br />
chronic-phase chronic mye<strong>lo</strong>id leukemia after failure of imatinib<br />
therapy. B<strong>lo</strong>od. 2007;109(6):2303-9.<br />
23. Shah NP, Kim DW, Kantarjian H, et al. Potent, transient inhibit<strong>io</strong>n<br />
of BCR-ABL1 with dasatinib 100 mg daily achieves<br />
rapid and durable cytogenetic responses and high transformat<strong>io</strong>n-free<br />
survival rates in chronic phase chronic mye<strong>lo</strong>id<br />
leukemia patients with resistance, suboptimal response or<br />
intolerance to imatinib. Haemato<strong>lo</strong>gica. 2010;95:232-40.<br />
24. Cortes J, Kantarjian H, Brummendort TH, et al. Safety and<br />
efficacy of bosutinib (SKI-606) in patients with chronic phase<br />
chronic mye<strong>lo</strong>id leukemia fol<strong>lo</strong>wing resistance or intolerance<br />
to imatinib. J Clin Oncol 2010;28:Abstract 6502.<br />
25. Kantarjian H, O’Brien S, Talpaz M, et al. Outcome of patients<br />
with Philadelphia chromosome-positive chronic mye<strong>lo</strong>genous<br />
leukemia post-imatinib mesylate failure. Cancer. 2007;109:<br />
1556-60.<br />
26. Verma D, Kantarjian H, Jones D, Luthra R, Borthakur G,<br />
Verstovsek S, et al. Chronic mye<strong>lo</strong>id leukemia (CML) with<br />
P190BCR-ABL1: analysis of characteristics, outcomes, and<br />
prognostic significance. B<strong>lo</strong>od. 2009;114:2232-5.<br />
27. Verma D, Kantarjian H, Shan J, O’Brien S, Estrov Z, Garcia-<br />
Manero G, et al. Survival outcomes for c<strong>lo</strong>nal evolut<strong>io</strong>n in<br />
London, United Kingdom, June 9-12, 2011<br />
chronic mye<strong>lo</strong>id leukemia patients on second generat<strong>io</strong>n tyrosine<br />
kinase inhibitor therapy. Cancer. 2010;116:2673-81.<br />
28. Jabbour E, Jones D, Kantarjian H, O’Brien S, Tam C, Koller C,<br />
et al. Long-term outcome of patients with chronic mye<strong>lo</strong>id<br />
leukemia treated with second-generat<strong>io</strong>n tyrosine kinase<br />
inhibitors after imatinib failure is predicted by the in vitro sensitivity<br />
of BCR-ABL1 kinase domain mutat<strong>io</strong>ns. B<strong>lo</strong>od.<br />
2009;114:2037-43.<br />
29. Hochhaus A, Muller MC, Cortes JE, Kim DW, Mat<strong>lo</strong>ub Y,<br />
P<strong>lo</strong>ughman L et al. Dasatinib efficacy after imatinib failure by<br />
dosing schedule and baseline BCR-ABL1 mutat<strong>io</strong>n status in<br />
patients with chronic mye<strong>lo</strong>id leukemia in chronic phase<br />
(CML-CP). Haemato<strong>lo</strong>gica. 2008;93: 371-2.<br />
30. Tam C, Kantarjian H, Garcia-Manero G, Borthakur G, O’Brien<br />
S, Ravandi F, et al. Failure to achieve a major cytogenetic<br />
response by 12 months defines inadequate response in<br />
patients receiving ni<strong>lo</strong>tinib or dasatinib as second or subsequent<br />
line therapy for chronic mye<strong>lo</strong>id leukemia. B<strong>lo</strong>od.<br />
2008;112: 516-8.<br />
31. Cortes J, Talpza M, Bixby D, Deininger M, et al. A phase 1 trial<br />
of oral ponatinib (AP24534) in patients with refractory chronic<br />
mye<strong>lo</strong>genous leukemia (CML) and other hemato<strong>lo</strong>gic malignancies:<br />
emerging safety and clinical response findings. B<strong>lo</strong>od.<br />
2010;115:Abstract 210.<br />
32. Van Etten RA, Chan WW, Zaleskas VM, et al. DCC-2036: A<br />
novel switch pocket inhibitor of ABL tyrosine kinase with<br />
therapeutic efficacy against BCR-ABL1 T315I in vitro and in a<br />
CML mouse model. B<strong>lo</strong>od. 2007;110:Abstract 463.<br />
33. Cortes J, Wetzler M, Lipton J, et al. Subcutaneous Omacetaxine<br />
(OM) Treatment of Chronic Phase (CP) Chronic Mye<strong>lo</strong>id<br />
Leukemia (CML) Patients Fol<strong>lo</strong>wing Multiple Tyrosine Kinase<br />
Inhibitor (TKI) Failure. B<strong>lo</strong>od. 2010;116:Abstract 2290.<br />
Hemato<strong>lo</strong>gy Educat<strong>io</strong>n: the educat<strong>io</strong>n programme for the annual congress of the <strong>European</strong> Hemato<strong>lo</strong>gy Associat<strong>io</strong>n | 2011; 5(1) | 131 |